Nafamostat attenuated the impairment of fibrinolysis in animal sepsis model by suppressing the increase of plasminogen activator inhibitor type

Journal of Trauma - Injury, Infection and Critical Care

Volumn 60, Issue 4, 2006, Pages 859-864

  Hryszko, Tomasz ^a,b   Inaba, Keisuke ^a   Ihara, Hayato ^a   Suzuki, Yuko ^a   Mogami, Hideo ^a   Urano, Tetsumei ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

FDP; Fibrinolysis; PAI 1; Protease inhibitor; Sepsis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FIBRIN; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; NAFAMSTAT MESILATE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE INHIBITOR; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; TUMOR NECROSIS FACTOR ALPHA; GUANIDINE DERIVATIVE; NAFAMSTAT; SERINE PROTEINASE INHIBITOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; ENDOTOXEMIA; FIBRIN METABOLISM; FIBRINOGEN METABOLISM; FIBRINOLYSIS; KIDNEY FUNCTION; LIVER; LIVER FUNCTION; MALE; MORTALITY; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SEPSIS; SYMPTOMATOLOGY; THROMBIN TIME; THROMBOCYTE COUNT; THROMBOSIS; UREA NITROGEN BLOOD LEVEL; ANIMAL; BLOOD; DRUG EFFECT; DRUG INTERACTION; METABOLISM; WISTAR RAT;

ANIMALS; DRUG INTERACTIONS; FIBRINOGEN; FIBRINOLYSIS; GUANIDINES; INTERLEUKIN-10; LIPOPOLYSACCHARIDES; LIVER; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEASE INHIBITORS; RATS; RATS, WISTAR; SEPSIS; SERINE PROTEINASE INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33646476139     PISSN: 00225282     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ta.0000215566.74588.27     Document Type: Article

References (30)

1. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303-1310.
2. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 1999;341:586-592.
3. Dixon B. The role of microvascular thrombosis in sepsis. Anaesth Intensive Care. 2004;32:619-629.
4. Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb. 1989;9:87-115.
5. Urano T, Ihara H, Suzuki Y, Takada Y, Takada A. Coagulation-associated enhancement of fibrinolytic activity via a neutralization of PAI-1 activity. Semin Thromb Hemost. 2000;26:39-42.
6. Asakura H, Ontachi Y, Mizutani T, et al. An enhanced fibrinolysis prevents the development of multiple organ failure in disseminated intravascular coagulation in spite of much activation of blood coagulation. Crit Care Med. 2001;29:1164-1168.
7. Garcia-Femandez N, Lavilla FJ, Rocha E, Purroy A. Assessment of haemostatic risk factors in patients with acute renal failure associated with severe systemic inflammatory response syndrome. Development of a prognostic index. Nephron. 2002;92:97-104.
8. Menges T, Hermans PW, Little SG, et al. Plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism and prognosis of severely injured patients. Lancet. 2001;357:1096-1097.
9. Gando S, Nakanishi Y, Tedo I. Cytokines and plasminogen activator inhibitor-1 in posttrauma disseminated intravascular coagulation: relationship to multiple organ dysfunction syndrome. Crit Care Med. 1995;23:1835-1842.
10. Grandaliano G, Pontrelli P, Cerullo G, et al. Protease-activated receptor-2 expression in IgA nephropathy: a potential role in the pathogenesis of interstitial fibrosis. J Am Soc Nephrol. 2003; 14:2072-2083.
11. Sendo T, Sumimura T, Itoh Y, et al. Involvement of proteinase-activated receptor-2 in mast cell tryptase-induced barrier dysfunction in bovine aortic endothelial cells. Cell Signal. 2003;15:773-781.
12. Hitomi Y, Fujii S. Inhibition of various immunological reactions in vivo by a new synthetic complement inhibitor. Int Arch Allergy Appl Immunol. 1982;69:262-267.
13. Kato H, Inoue M, Yamamura Y, et al. Mechanism of polymorphonuclear leukocytes accumulation examined using inhibitors of complement and arachidonic acid cascade in rats treated with OK-432. Nat Immun Cell Growth Regul. 1989;8:290-300.
14. Asakura H, Suga Y, Aoshima K, et al. Marked difference in pathophysiology between tissue factor- and lipopolysaccharide-induced disseminated intravascular coagulation models in rats. Crit Care Med. 2002;30:161-164.
15. Schleef RR, Wagner NV, Loskutoff DJ. Detection of both type 1 and type 2 plasminogen activator inhibitors in human cells. J Cell Physiol. 1988;134:269-274.
16. Urano T, Strandberg L, Johansson LB, Ny T. A substrate-like form of plasminogen-activator-inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate. Eur J Biochem. 1992; 209:985-992.
17. Moloney WC, Mcpherson K, Fliegelman L. Esterase activity in leukocytes demonstrated by the use of naphthol AS-D chloroacetate substrate. J Histochem Cytochem. 1960;8:200-207.
18. Asakura H, Sano Y, Omote M, et al. Significance of decreased plasma D-dimer levels following lipopolysaccharide-induced disseminated intravascular coagulation in rats. Int J Hematol. 2004; 79:394-399.
19. Hamsten A, De Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
20. Hermans PW, Hibberd MI, Booy R, et al. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet. 1999;354:556-560.
21. Abrahamsson T, Nerme V, Stromqvist M, et al. Anti-thrombotic effect of a PAI-1 inhibitor in rats given endotoxin. Thromb Haemost. 1996;75:118-126.
22. Montes R, Declerck PJ, Calvo A, et al. Prevention of renal fibrin deposition in endotoxin-induced DIC through inhibition of PAI-1. Thromb Haemost. 2000;84:65-70.
23. Podor TJ, Hirsh J, Gelehrter TD, et al. Type 1 plasminogen activator inhibitor is not an acute phase reactant in rats. Lack of IL-6- and hepatocyte-dependent synthesis. J Immunol. 1993; 150:225-235.
24. Raaphorst J, Johan Groeneveld AB, Bossink AW, Erik Hack C. Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients. Thromb Haemost. 2001;86:543-549.
25. Ruf W, Dorfleutner A, Riewald M. Specificity of coagulation factor signaling. J Thromb Haemost. 2003;1:1495-503.
26. Nakatsuka M, Asagiri K, Noguchi S, Habara T, Kudo T. Nafamostat mesilate, a serine protease inhibitor, suppresses lipopolysaccharide-induced nitric oxide synthesis and apoptosis in cultured human trophoblasts. Life Sci. 2000;67:1243-1250.
27. Wojta J, Kaun C, Zorn G, et al. C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils. Blood. 2002;100:517-523.
28. Onaya J, Kyogashima M, Sunose A, et al. Effects of dermatan sulfate, a heparin cofactor II mediated thrombin inhibitor, on the endotoxin-induced disseminated intravascular coagulation model in the rat: comparison with low-molecular weight heparin, nafamostat mesilate and argathroban. Jpn J Pharmacol. 1998; 76:397-404.
29. Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Effect of nafamostat mesilate on pulmonary vascular injury induced by lipopolysaccharide in rats. Am J Respir Crit Care Med. 1997; 155:711-718.
30. Minamiya Y, Saito S, Nakamura M, et al. Nafamostat mesilate attenuates radical formation in the rat lung infused with endotoxin. Shock. 2002;18:255-260.